Updates on Breast Cancer: Diagnosis and Management

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 97

Special Issue Editor


E-Mail Website
Guest Editor
The London Breast Institute, Princess Grace Hospital, 42-52 Nottingham Place, London W1U 5NY, UK
Interests: breast cancer; stem cells; gene profiling; autophagy; liquid biopsy; microRNA
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

I am delighted to invite you to contribute articles to a Special Issue of Diagnostics, a renowned journal with an impact factor of 3.6. As the Guest Editor of this Special Issue, titled "Breast Disease, Diagnosis, and Management," I am eager to showcase the latest advances in breast cancer diagnosis and treatment.

Breast cancer remains a significant healthcare challenge, and through this Special Issue, we aim to highlight innovative approaches and emerging trends that are shaping the landscape of breast cancer management. Your valuable contributions can illuminate novel diagnostic techniques, therapeutic interventions, prognostic markers, and multidisciplinary approaches, revolutionizing how we understand and treat this disease.

We welcome original research articles, review papers, and perspectives on breast cancer diagnosis and management. Your insights and expertise will undoubtedly enrich the discourse and contribute to advancing our collective understanding of breast cancer.

This invitation is an opportunity to showcase your research to a global audience of clinicians, researchers, and healthcare professionals. We look forward to receiving your submissions and collaborating to make this Special Issue successful.

Prof. Dr. Kefah Mokbel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • breast tumor
  • mammography
  • tissue biopsy
  • breast ultrasound
  • diagnosis and management
  • prognosis
  • treatment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

10 pages, 882 KiB  
Systematic Review
Assessing the Efficacy of Radioactive Iodine Seed Localisation in Targeted Axillary Dissection for Node-Positive Early Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy: A Comprehensive Review and Pooled Analysis
by Munaser Alamoodi, Umar Wazir, Janhavi Venkataraman, Reham Almukbel and Kefah Mokbel
Diagnostics 2024, 14(11), 1175; https://doi.org/10.3390/diagnostics14111175 (registering DOI) - 2 Jun 2024
Abstract
Targeted axillary dissection (TAD), employing marked lymph node biopsy (MLNB) alongside sentinel lymph node biopsy (SLNB), is increasingly recognised for its efficacy in reducing false negative rates (FNRs) in node-positive early breast cancer patients receiving neoadjuvant systemic therapy (NST). One such method, 125 [...] Read more.
Targeted axillary dissection (TAD), employing marked lymph node biopsy (MLNB) alongside sentinel lymph node biopsy (SLNB), is increasingly recognised for its efficacy in reducing false negative rates (FNRs) in node-positive early breast cancer patients receiving neoadjuvant systemic therapy (NST). One such method, 125I radioactive seed localisation (RSL), involves implanting a seed into a biopsy-proven lymph node either pre- or post-NST. This systematic review and pooled analysis aimed to assess the performance of RSL in TAD among node-positive patients undergoing NST. Six studies, encompassing 574 TAD procedures, met the inclusion criteria. Results showed a 100% successful deployment rate, with a 97.6% successful localisation rate and a 99.8% retrieval rate. Additionally, there was a 60.0% concordance rate between SLNB and MLNB. The FNR of SLNB alone was significantly higher than it was for MLNB (18.8% versus 5.3%, respectively; p = 0.001). Pathological complete response (pCR) was observed in 44% of cases (248/564). On average, the interval from 125I seed deployment to surgery was 75.8 days (range: 0–272). These findings underscore the efficacy of RSL in TAD for node-positive patients undergoing NST, enabling precise axillary pCR identification and facilitating the safe omission of axillary lymph node dissection. Full article
(This article belongs to the Special Issue Updates on Breast Cancer: Diagnosis and Management)
Show Figures

Figure 1

Back to TopTop